NASDAQ: SKINSkinhealth Systems Inc Stock
$0.93+0.03 (+3.33%)
Updated May 6, 2026
SKIN Price
$0.93
Fair Value Price
N/A
Market Cap
$119.21M
52 Week Low
$0.76
52 Week High
$2.69
P/E
-11.66x
P/B
1.95x
P/S
0.58x
PEG
N/A
Dividend Yield
N/A
Revenue
$300.79M
Earnings
-$9.52M
Gross Margin
65.3%
Operating Margin
4.45%
Profit Margin
-3.2%
Debt to Equity
7.19
Operating Cash Flow
$37M
Beta
1.89
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
SKIN Overview
The Beauty Health Company manufactures and sells aesthetic technologies and products worldwide. The company's flagship brand, HydraFacial, created the category of hydra dermabrasion by using a patented system to cleanse, peel, exfoliate, extract, infuse, and hydrate the skin with proprietary solutions and serums. It also offers HydraFacial Nation App, an app that allows consumers to learn about their skin health, discover treatment options, and track their treatments over time. The Beauty Health was founded in 1997 and is headquartered in Long Beach, CA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine SKIN's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Household & Personal Product
Industry Rating
C
SKIN
Ranked#14 of 20
Ranked#14 of 20
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $42.22 | B | |
| $25.59 | B | |
| $85.03 | C |
Be the first to know about important SKIN news, forecast changes, insider trades & much more!
SKIN News
Overview
Due Diligence Score
–
Industry Average (31)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how SKIN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SKIN is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
SKIN is good value based on its book value relative to its share price (1.95x), compared to the US Household & Personal Products industry average (6.5x)
P/B vs Industry Valuation
SKIN is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more SKIN due diligence checks available for Premium users.
Valuation
SKIN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-11.66x
Industry
14.1x
Market
20.8x
SKIN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.95x
Industry
6.5x
SKIN is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
SKIN's financial health
Profit margin
Revenue
$82.4M
Net Income
-$8.1M
Profit Margin
-9.8%
SKIN's Earnings (EBIT) of $13.39M... subscribe to Premium to read more.
Interest Coverage Financials
SKIN's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$499.8M
Liabilities
$438.7M
Debt to equity
7.19
SKIN's short-term assets ($309.52M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SKIN's short-term assets ($309.52M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SKIN's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
SKIN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$15.2M
Investing
-$1.4M
Financing
-$512.0k
SKIN's operating cash flow ($37.49M)... subscribe to Premium to read more.
Debt Coverage Financials
SKIN vs Household & Personal Product Stocks
Skinhealth Systems Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.